OneSource, Xbrane Partner for Global Biosimilar Supply

13 Jun 2025 CW Team

Xbrane’s biosimilar pipeline targets an estimated EUR 23 billion in annual peak sales of the reference biologics. Its lead candidate, Ximluci—a biosimilar of ranibizumab—has already received market authorisation in Europe and was launched in 2023. The product is currently under regulatory review for entry into the United States market.

Under the agreement, Xbrane will transfer the technology for selected biosimilars to OneSource’s state-of-the-art integrated Drug Substance and Drug Product (DS/DP) facility located in Bangalore, India. This move is aimed at bolstering Xbrane’s global supply chain and enhancing the regulatory readiness of OneSource’s biologics infrastructure. It is expected to accelerate approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

As part of the collaboration, OneSource has also taken part in Xbrane’s most recent funding round, underlining the long-term strategic alignment between the two firms.

Neeraj Sharma, Managing Director and CEO of OneSource Specialty Pharma, commented, “The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbrane’s proven success in biosimilar development, combined with OneSource’s fully integrated biologics platform, creates a strong foundation for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the world’s leading biotech companies.”

Martin Åmark, CEO of Xbrane Biopharma, added, “Our partnership with OneSource gives us access to top-tier, cost-competitive manufacturing and expertise for our biosimilars. This is essential for our global competitiveness and our commitment to providing affordable medicines to patients and payers.”

The collaboration is expected to enhance the reach of affordable biosimilar therapies globally, while also positioning OneSource as a leading biologics CDMO with strong regulatory and manufacturing capabilities.

OneSource Specialty Pharma Limited, a multi-modality specialty pharmaceutical contract development and manufacturing organisation (CDMO), has announced a strategic manufacturing partnership with Sweden-based Xbrane Biopharma AB (Nasdaq: XBRANE), a leading biotechnology firm. The collaboration will focus on the commercial production of Xbrane’s biosimilar portfolio.Xbrane’s biosimilar pipeline targets an estimated EUR 23 billion in annual peak sales of the reference biologics. Its lead candidate, Ximluci—a biosimilar of ranibizumab—has already received market authorisation in Europe and was launched in 2023. The product is currently under regulatory review for entry into the United States market.Under the agreement, Xbrane will transfer the technology for selected biosimilars to OneSource’s state-of-the-art integrated Drug Substance and Drug Product (DS/DP) facility located in Bangalore, India. This move is aimed at bolstering Xbrane’s global supply chain and enhancing the regulatory readiness of OneSource’s biologics infrastructure. It is expected to accelerate approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).As part of the collaboration, OneSource has also taken part in Xbrane’s most recent funding round, underlining the long-term strategic alignment between the two firms.Neeraj Sharma, Managing Director and CEO of OneSource Specialty Pharma, commented, “The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbrane’s proven success in biosimilar development, combined with OneSource’s fully integrated biologics platform, creates a strong foundation for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the world’s leading biotech companies.”Martin Åmark, CEO of Xbrane Biopharma, added, “Our partnership with OneSource gives us access to top-tier, cost-competitive manufacturing and expertise for our biosimilars. This is essential for our global competitiveness and our commitment to providing affordable medicines to patients and payers.”The collaboration is expected to enhance the reach of affordable biosimilar therapies globally, while also positioning OneSource as a leading biologics CDMO with strong regulatory and manufacturing capabilities.

Infrastructure Urban

05 Nov 2025

TBO Tek Q2 Profit Climbs 12%, Revenue Surges 26% YoY

TBO Tek Limited one of the world’s largest travel distribution platforms, reported a solid performance for Q2 FY26 with a 26 per cent year-on-year increase in revenue to Rs 5.68 billion, reflecting broad-based growth and improving profitability.The company recorded a Gross Transaction Value (GTV) of Rs 8,901 crore, up 12 per cent YoY, driven by strong performance across Europe, MEA, and APAC regions. Adjusted EBITDA before acquisition-related costs stood at Rs 1.04 billion, up 16 per cent YoY, translating into an 18.32 per cent margin compared to 16.56 per cent in Q1 FY26. Profit after tax r..

Infrastructure Energy

05 Nov 2025

Northern Graphite, Rain Carbon Secure R&D Grant for Greener Battery Materials

Northern Graphite Corporation and Rain Carbon Canada Inc, a subsidiary of Rain Carbon Inc, have jointly received up to C$860,000 (€530,000) in funding under the Canada–Germany Collaborative Industrial Research and Development Programme to develop sustainable battery anode materials.The two-year, C$2.2 million project aims to transform natural graphite processing by-products into high-performance, battery-grade anode material (BAM). Supported by the National Research Council of Canada Industrial Research Assistance Programme (NRC IRAP) and Germany’s Federal Ministry for Economic Affairs a..

Infrastructure Urban

05 Nov 2025

Antony Waste Q2 Revenue Jumps 16%; Subsidiary Wins Rs 3,200 Cr WtE Projects

Antony Waste Handling Cell Limited (AWHCL), a leading player in India’s municipal solid waste management sector, announced a 16 per cent year-on-year increase in total operating revenue to Rs 2.33 billion for Q2 FY26. The growth was driven by higher waste volumes, escalated contracts, and strong operational execution.EBITDA rose 18 per cent to Rs 570 million, with margins steady at 21.6 per cent, while profit after tax stood at Rs 173 million, up 13 per cent YoY. Revenue from Municipal Solid Waste Collection and Transportation (MSW C&T) reached Rs 1.605 billion, and MSW Processing re..